Industry Trend Analysis - Cosentyx Trial Against Biosimilar Adalimumab Reveals Novartis' Market Outlook - MAR 2018


BMI View: Novartis is keen to develop the suite of indications for Cosentyx and it is sensible to test the drug against AbbVie ' s adalimumab drug, Humira, which is one of the major biologics it will compete against. However, testing against its own subsidiary ' s biosimilar adalimumab as well indicates that Novartis sees the biosimilar market as a separate entity to the biological market. T he trial results will prove to be a u seful marketing tool for Sandoz in establishing its adalimumab as a direct competitor for Humira.

Novartis has initiated SURPASS, a head-to-head trial of its IL-17A drug, Cosentyx (secukinumab), versus a proposed biosimilar adalimumab in ankylosing spondylitis (AS). SURPASS is the first head-to-head trial in AS investigating superiority of Cosentyx in slowing spinal bone damage versus a proposed biosimilar adalimumab. The trial is currently recruiting patients, with the 'first patient first visit' already achieved in November 2017. Adalimumab is marketed by AbbVie as Humira, but the proposed biosimilar to be used in the trials is one that is under development by Novartis' subsidiary, Sandoz.

SURPASS and EXCEED are part of a larger rheumatology programme for Cosentyx. EXCEED is a head-to-head trial of Cosentyx versus Humira in psoriatic arthritis (PsA), which is already recruiting. EXCEED is the first large double-blind head-to-head trial versus Humira in PsA investigating the potential superiority of Cosentyx on ACR20 at 52 weeks as the primary endpoint. This is a one-year, multicentre, randomised, double-blind, active control, Phase IIIb study evaluating the efficacy of Cosentyx monotherapy compared with Humira monotherapy in patients with active PsA who are naive to biologic therapy. The study will include a large patient population involving over 800 biologic-naive patients with PsA.

Cosentyx Sales Minor Compared To Humira
Cosentyx And Humira Quarterly Sales (USDmn)
Source: Novartis, AbbVie, BMI

This article is part of our Western Europe coverage. To access this article subscribe now or sign up for free trial